Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older

ConclusionsIn pediatric patients 6 years of age and older, treatment with dupilumab resulted in rapid and consistent improvement in the extent and signs of AD across all anatomical regions.ClinicalTrials.gov IdentifiersLIBERTY AD ADOL (NCT03054428) and LIBERTY AD PEDS (NCT03345914).Does dupilumab provide improvement in atopic dermatitis across all anatomical regions in children and adolescents? (MP4 48,385 kb)

http://rd.springer.com/10.1007/s13555-021-00568-y

Source: Dermatology and Therapy - August 24, 2021 Category: Dermatology Source Type: research